Clinical Practice Guidelines - National Health and Medical Research ...
Clinical Practice Guidelines - National Health and Medical Research ...
Clinical Practice Guidelines - National Health and Medical Research ...
Create successful ePaper yourself
Turn your PDF publications into a flip-book with our unique Google optimized e-Paper software.
113. Cunningham, D., S. Falk, <strong>and</strong> D. Jackson, <strong>Clinical</strong> <strong>and</strong> economic benefits of irinotecan in<br />
combination with 5-fluorouracil <strong>and</strong> folinic acid as first line treatment of metastatic colorectal<br />
cancer. British Journal of Cancer, 2002. 86(11): p. 1677–83.<br />
114. Poston, G., et al., Costs of neoadjuvant chemotherapy <strong>and</strong> surgery in patients with liver<br />
metastases from advanced colorectal cancer. Journal of <strong>Medical</strong> Economics, 2001. 4: p. 167–<br />
177.<br />
115. Koperna, T. <strong>and</strong> D. Semmler, Innovative chemotherapies for stage III colon cancer: a costeffectiveness<br />
study. Hepato-Gastroenterology, 2003. 50(54): p. 1903–9.<br />
116. Focan, C., Pharmaco-economic comparative evaluation of combination chronotherapy vs.<br />
st<strong>and</strong>ard chemotherapy for colorectal cancer. Chronobiology International, 2002. 19(1): p.<br />
289–97.<br />
117. Murad, A., et al., A pharmacoeconomic comparison of UFT <strong>and</strong> 5-FU chemotherapy for<br />
colorectal cancer in South America. Oncology (Huntington), 1997. 11(9 Suppl 10): p. 128–<br />
35.<br />
118. Monz, B.U., et al., Cost effectiveness of adding folinic acid to fluorouracil plus levamisole as<br />
adjuvant chemotherapy in patients with colon cancer in Germany. Pharmacoeconomics, 2003.<br />
21(10): p. 709–19.<br />
119. Nicholls, C., et al., Cost-effectiveness of combination chemotherapy (oxaliplatin or irinotecan<br />
in combination with 5-FU/FA) compared with 5-FU/FA alone. Journal of <strong>Medical</strong><br />
Economics, 2001. 4: p. 115–125.<br />
120. Lloyd Jones, M., et al., A rapid <strong>and</strong> systematic review of the evidence for the clinical<br />
effectiveness <strong>and</strong> cost-effectiveness of irinotecan, oxaliplatin <strong>and</strong> raltitrexed for the treatment<br />
of advanced colorectal cancer. <strong>Health</strong> Technology Assessment (Winchester, Engl<strong>and</strong>), 2001.<br />
5(25): p. 1–128.<br />
121. Hale, J.P., et al., Costs <strong>and</strong> consequences of different chemotherapy regimens in metastatic<br />
colorectal cancer. British Journal of Cancer, 2002. 86(11): p. 1684–90.<br />
122. Rowe, M., et al., New face for a familiar friend: The de Gramont regimen in the treatment of<br />
metastatic colorectal cancer given as an outpatient: A feasibility study. Journal of Oncology<br />
Pharmacy <strong>Practice</strong>, 2002. 8(2–3): p. 97–103.<br />
123. Scott, L.C. <strong>and</strong> C. Twelves, Cost-effective strategies in the management of advanced<br />
colorectal cancer. American Journal of Cancer, 2003. 2(2): p. 111–124.<br />
124. Van Den Brink, M., et al., Cost-utility analysis of preoperative radiotherapy in patients with<br />
rectal cancer undergoing total mesorectal excision: a study of the Dutch Colorectal Cancer<br />
Group. Journal of <strong>Clinical</strong> Oncology, 2004. 22(2): p. 244–53.<br />
125. Dahlberg, M., et al., Cost-effectiveness of preoperative radiotherapy in rectal cancer: results<br />
from the Swedish Rectal Cancer Trial. International Journal of Radiation Oncology, Biology,<br />
Physics, 2002. 54(3): p. 654–60.<br />
126. Shetty, S.K., et al., Cost-effectiveness of percutaneous radiofrequency ablation for malignant<br />
hepatic neoplasms. Journal of Vascular & Interventional Radiology, 2001. 12(7): p. 823–33.<br />
288<br />
The prevention, early detection <strong>and</strong> management of colorectal cancer
Change language